Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Med.

Sec. Obstetrics and Gynecology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1671823

Prognostic Impact of Low-Volume Nodal Metastases in Endometrial Cancer: A Systematic Review of Molecular Subtypes

Provisionally accepted
  • 1King Saud University Department of Obstetrics and Gynecology, Riyadh, Saudi Arabia
  • 2King Saud University, Riyadh, Saudi Arabia

The final, formatted version of the article will be published soon.

Introduction: Endometrial cancer (EC) is the most common gynecologic malignancy, with lymph node metastases (LNM) serving as a key prognostic factor. Low-volume metastases (LVM), including micrometastases (MM; >0.2–≤2 mm) and isolated tumor cells (ITCs; ≤0.2 mm), detected via sentinel lymph node (SLN) ultrastaging, remain controversial regarding their clinical impact. This systematic review evaluates the prognostic significance of LVM, stratified by The Cancer Genome Atlas (TCGA) molecular subtypes. Methods: Following PRISMA guidelines, this study conducted a systematic review (PROSPERO: CRD420251067512) of research published from 2013 to 2025. Inclusion criteria comprised EC patients with LVM who underwent nodal staging (SLN or lymphadenectomy) and molecular classification. Outcomes included progression-free survival (PFS), overall survival (OS), recurrence, and the impact of adjuvant therapy. Risk of bias was assessed using the Newcastle-Ottawa Scale and ROBINS-I. Results: Ten studies (n = 4,482 patients) were included. Micrometastases were associated with worse PFS (HR 2.45, 95% CI 1.89–3.18) and OS (HR 1.75, 95% CI 1.40–2.18), particularly in p53-abnormal (p53abn) subtypes (HR 2.9, 95% CI 2.3–3.7). ITCs showed minimal prognostic impact (PFS HR 1.3, 95% CI 1.0–1.6; OS HR 1.1, 95% CI 0.88–1.37). SLN mapping with ultrastaging improved detection (72% increase vs. H&E) without compromising survival compared to lymphadenectomy. Molecular stratification revealed that POLE-ultramutated tumors retained an excellent prognosis despite the presence of LVM. Discussion: The prognostic relevance of LVM varies substantially by metastatic burden and molecular subtype. Micrometastases may warrant escalation of adjuvant therapy, whereas ITCs may not require systemic treatment in favorable molecular subtypes. SLN ultrastaging should be standardized, and integration of TCGA classification into routine clinical decision-making is essential. Future clinical trials must validate subtype-specific management strategies.

Keywords: endometrial cancer, low-volume metastases, Sentinel Lymph Node Biopsy, Molecular classification, Ultrastaging, Prognostic stratification

Received: 23 Jul 2025; Accepted: 11 Sep 2025.

Copyright: © 2025 Bassi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ali Bassi, ali.bassi.dr@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.